Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
Date:3/3/2011

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it expects to report fourth quarter and full year 2010 financial results after the NASDAQ Global Market closes on Thursday, March 10, 2011.  The Company also expects to host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and highlights for the fourth quarter and full year 2010, as well as provide a corporate update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.  Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.  

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com. ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale CommunicationsJason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
2. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
3. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
4. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
5. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
6. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
7. Optimer Pharmaceuticals Announces Key Additions to Management Team
8. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
9. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
10. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 2017 The Bio Supply Management Alliance (BSMA) ... Fremont and the Biomedical Manufacturing Network to ... California by providing a platform ... fostering workforce development. The primary focus of this alliance ... as well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... U.S. Food and Drug Administration (FDA) has notified the Company ... its Zhejiang, China manufacturing facility has ... successful clearance of the Warning Letter related to our ... measure of the progress we have made in our ongoing ...
(Date:6/11/2017)... INDIANAPOLIS , June 10, 2017  Eli Lilly and ... results from three Phase 3 studies of galcanezumab, an ... migraine, including late-breaking data on several key secondary endpoints ... Detailed results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... (AHS) annual scientific meeting in Boston ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Doorknobs are for convenience, deadbolts are ... getting a guard dog or having an alarm system installed. But unless there is ... entry. Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX says: “In the ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... By scoring ... its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's ... top 1% of all charities reviewed by Charity Navigator and earns ANRF a spot ...
(Date:6/23/2017)... Va. (PRWEB) , ... June 23, 2017 , ... The ... the president's nominee for deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. ... Veterans Affairs. , Bowman brings an intimacy with the issues and challenges ...
(Date:6/23/2017)... New York, NY (PRWEB) , ... June 23, 2017 , ... ... prefer to watch it while others prefer to read it, and some people don't ... printed versus visual pornography. Here's what they found: , Erotic literature can give readers ...
(Date:6/23/2017)... D.C. (PRWEB) , ... June 23, 2017 , ... ... during cooking is essential, and two new videos highlight the importance of correctly ... Specialist Christine Bruhn, Ph.D., who has done extensive research on consumer food safety ...
Breaking Medicine News(10 mins):